Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $37.1550 (0.23%) ($37.1550 - $37.1550) on Thu. Jul. 15, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.91% (three month average) | RSI | 46 | Latest Price | $37.1550(0.23%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.7% a day on average for past five trading days. | Weekly Trend | TGTX declines -0.6% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(63%) ARKK(59%) IBB(59%) IWO(59%) | Factors Impacting TGTX price | TGTX will decline at least -1.455% in a week (0% probabilities). VIXM(-46%) VXX(-38%) UUP(-19%) UNG(-3%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.455% (StdDev 2.91%) | Hourly BBV | -0.8 () | Intraday Trend | 0% | | | |
|
Resistance Level | $38.56 | 5 Day Moving Average | $38.5(-3.49%) | 10 Day Moving Average | $38.77(-4.17%) | 20 Day Moving Average | $38.56(-3.64%) | To recent high | -19.1% | To recent low | 14.6% | Market Cap | $4.706b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |